Platinum-Paeonol Complexes as ERK Inhibitors for Melanoma

Data from a study on synthesized platinum-paeonol complexes PAP and DPAP, which inhibit melanoma and relieve associated pain. The research demonstrates DPAP's antimelanoma activity via DNA damage, mitochondrial pathway apoptosis, and inhibition of p-MEK1/2 and p-ERK1/2 expression. The dataset includes findings on DPAP's potential to relieve cancer pain and its unique upregulation of PD-L1 for combination immunotherapy.

Use Cases

• Analyze the relationship between p-ERK1/2 inhibition and metastasis suppression in melanoma models.
• Investigate the correlation between p-ERK1/2 and COX-2 expression in nerve cells with cancer pain relief.
• Model the combined antitumor efficacy of DPAP and anti-PD-1 antibody based on PD-L1 upregulation data.
• Study the apoptotic effects triggered via the mitochondrial pathway following DNA and mitochondrial damage.

Strengths

• Data originates from a peer-reviewed scientific study on a novel therapeutic approach.
• Findings include in vitro and in vivo experimental validation of the complexes' effects.
• The dataset captures a unique dual mechanism targeting both tumor growth and associated pain.

Limitations

• The dataset is extremely small at 304.0 B, indicating it likely contains only summary or metadata, not raw experimental data.
• Specific data structure, column names, and row counts are unknown, limiting direct analytical utility.
• Findings are specific to the studied platinum-paeonol complexes and melanoma models, limiting generalizability.

Provenance

Source

figshare, authored by Yehong Tan.

Collection Method

Experimental data from the synthesis and biological testing of platinum-paeonol complexes.

Freshness

Last updated March 24, 2026.